Long-term metabolic effectiveness and safety of growth hormone replacement therapy in patients with adult growth hormone deficiency: a single-institution study in Japan
Authors' conclusion
We demonstrated the metabolic effectiveness and safety of GHRT in Japanese patients with AGHD over a long follow-up period of 16 years.
Study context
- Population
- Japanese patients with adult GHD receiving growth hormone replacement therapy (GHRT); 46.4% males, 70.9% adult-onset GHD
- Participants
- 110 patients
- Outcome
- Long-term metabolic effects of GHRT
- Follow-up
- Up to 196 months (median 68 months)
Methodological detailssingle-institution, Patients followed >11 years: 17
- Single-institution
- Patients followed >11 years: 17
Main finding
As reported in the abstract
- IGF-1 SD score increased after start of GHRT and remained constant for >11 years
- BMI increased
- Waist circumference decreased in the short term but increased in the long term
- Diastolic blood pressure decreased 1-5 years after start of GHRT; systolic blood pressure increased 11 years after GHRT
- Long-term decrease in LDL-C, increase in HDL-C, decrease in aspartate and alanine aminotransferase
- HbA1c increased after 3 years
- BMD in lumbar spine and total hip increased significantly 3 years after start of GHRT
- Linear mixed-effects model
Observational data: associations, not effects.
Safety
- Number of adverse events
- 8
Original publication
Long-term metabolic effectiveness and safety of growth hormone replacement therapy in patients with adult growth hormone deficiency: a single-institution study in Japan. Pituitary. Published 19 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →